Temazepam Nitrazepam Lorazepam No Dose Adjustment Temazepam, Nitrazepam, Lorazepam: For benzodiazepines which are not metabolized by CYP3A (e.g., temazepam, nitrazepam, lorazepam), a clinically important interaction with clarithromycin is unlikely.
Source: FDA drug label - clarithromycin
7.6 Temazepam Under steady-state conditions for duloxetine delayed-release capsules (20 mg qhs) and temazepam (30 mg qhs), the pharmacokinetics of duloxetine were not affected by co-administration.
Source: FDA drug label - duloxetine
7.6 Temazepam Under steady-state conditions for duloxetine (20 mg qhs) and temazepam (30 mg qhs), the pharmacokinetics of duloxetine were not affected by co-administration.
Source: FDA drug label - duloxetine hydrochloride
CHCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid and temazepam.
Source: FDA drug label - etonogestrel and ethinyl estradiol vaginal ring
Other Drugs Clinical effect Concomitant use of COCs may decrease systemic exposure of acetaminophen, morphine, salicylic acid, and temazepam.
Source: FDA drug label - levonorgestrel and ethinyl estradiol
CHCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, and temazepam.
Source: FDA drug label - norelgestromin and ethinyl estradiol
COCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, and temazepam.
Source: FDA drug label - norethindrone acetate and ethinyl estradiol
COCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine.
Source: FDA drug label - norethindrone and ethinyl estradiol
COCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine.
Source: FDA drug label - norgestimate and ethinyl estradiol